肿瘤学市场规模、份额及成长分析（按治疗类型、药物类别、给药途径、癌症类型、最终用户、分销管道和地区）－2025-2032 年产业预测

2023 年癌症治疗市场规模价值 2,106.9 亿美元，预计将从 2024 年的 2,315.5 亿美元成长到 2032 年的 4,927.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 9.9%。

由于全球癌症发病率不断上升，癌症治疗行业预计将经历显着增长。对肿瘤学研究的投入不断增加以及对先进治疗方案的需求不断增长，为该领域的公司创造了良好的机会。此外，针对各种癌症的基因治疗和个人化医疗的日益普及也推动了这个市场的发展。此外，联合治疗的兴起和政府对肿瘤学研究的津贴增加预计将在未来几年推动销售成长。然而，在这种不断变化的情况下，抗药性、癌症异质性以及治疗的潜在副作用等挑战仍然是医疗保健提供者关注的重大问题。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局

癌症治疗市场规模（按治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 化疗
• 免疫疗法
• 标靶治疗
• 荷尔蒙疗法
• 放射治疗
• 干细胞移植
• 基因治疗
• 其他新型治疗方法

癌症治疗市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• 烷化剂
• 抗代谢物
• 抗肿瘤抗生素
• 拓朴异构酶抑制剂
• 有丝分裂抑制剂
• 荷尔蒙疗法
• 免疫查核点抑制剂
• 其他的

癌症治疗市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概览
• 口服
• 静脉
• 皮下
• 肌肉注射
• 局部的
• 其他的

癌症治疗市场规模（按癌症类型和复合年增长率） (2025-2032)

• 市场概览
• 肺癌
• 乳癌
• 摄护腺癌
• 大肠直肠癌
• 皮肤癌
• 血癌（白血病、淋巴瘤等）
• 消化道癌
• 妇科癌症
• 呼吸道/肺癌
• 其他类型的癌症

癌症治疗市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 专科诊所
• 癌症及放射治疗中心

癌症治疗市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概览
• 医院药房
• 零售药局
• 网路药局

癌症治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Bristol-Myers Squibb（USA）
• Merck & Co.（USA）
• Roche（Switzerland）
• Pfizer（USA）
• Novartis（Switzerland）
• Johnson & Johnson（USA）
• AstraZeneca（UK）
• GlaxoSmithKline（UK）
• Amgen（USA）
• AbbVie（USA）
• Sanofi（France）
• Bayer（Germany）
• Eli Lilly（USA）
• Takeda Pharmaceutical（Japan）
• Astellas Pharma（Japan）
• Gilead Sciences（USA）
• Celgene（USA）
• Daiichi Sankyo（Japan）
• Biogen（USA）
• Dr. Reddy's Laboratories（India）

结论和建议

Cancer Therapeutics Market size was valued at USD 210.69 billion in 2023 and is poised to grow from USD 231.55 billion in 2024 to USD 492.75 billion by 2032, growing at a CAGR of 9.9% during the forecast period (2025-2032).

The cancer therapeutics industry is poised for significant growth as the global prevalence of cancer continues to rise. Increased investments in oncology research and an escalating demand for advanced treatment options are creating promising opportunities for companies in this sector. The market is further enhanced by the escalating adoption of gene therapies and personalized medicine tailored for various cancer types. Additionally, the rise of combination therapies and heightened government funding for oncology research are expected to drive sales in the coming years. However, challenges such as drug resistance, the heterogeneity of cancer, and potential adverse effects of treatments remain critical concerns for providers in this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Therapeutics Market Segments Analysis

Global Cancer Therapeutics Market is segmented by Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Radiation Therapy, Stem Cell Transplant, Gene Therapy and Other Emerging Therapies. Based on Drug Class, the market is segmented into Alkylating Agents, Antimetabolites, Antitumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Hormone Therapies, Immune Checkpoint Inhibitors and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous, Subcutaneous, Intramuscular, Topical and Others. Based on Cancer Type, the market is segmented into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Skin Cancer, Blood Cancer (Leukemia, Lymphoma, etc.), Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer and Other Cancer Types. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Cancer and Radiation Therapy Centers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Therapeutics Market

The rise in cancer cases globally can be largely attributed to poor lifestyle choices and the increasing prevalence of unhealthy habits among individuals. This alarming trend has contributed to a substantial increase in the number of individuals diagnosed with cancer, thereby driving the demand for cancer therapeutics. As more people require effective treatments to combat this disease, the cancer therapeutics market is experiencing notable growth. The urgent need for innovative therapies to address the escalating cancer burden is highlighting the importance of investment and research in this market, further fueling its expansion in response to the growing health crisis.

Restraints in the Cancer Therapeutics Market

The rapid evolution of cancer cells and tumors has led to increasing resistance to various treatment modalities, significantly impacting the sales of cancer therapeutics. This resistance not only hampers the effectiveness of existing drugs but also poses a considerable challenge for the entire cancer therapeutics market, ultimately hindering its growth. As therapies become less effective against resistant tumors, the demand for innovative treatments rises, yet the slow pace of drug development and approval can exacerbate market stagnation. Consequently, the challenges posed by evolving cancer biology and drug resistance serve as a significant restraint on the progress of the cancer therapeutics market.

Market Trends of the Cancer Therapeutics Market

The Cancer Therapeutics market is witnessing a significant trend towards the integration of artificial intelligence (AI) in drug discovery and development processes. Companies are increasingly leveraging AI technologies to streamline research initiatives, identify novel drug targets, and enhance the efficacy of existing treatments. This trend not only accelerates innovation but also reduces time-to-market for new therapies. Additionally, AI is poised to play a broader role across various facets of the cancer therapeutics landscape, including personalized medicine and patient management, thereby driving efficiency and improving clinical outcomes. As this trend matures, it is expected to reshape the competitive dynamics of the market significantly.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Cancer Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormonal Therapy
• Radiation Therapy
• Stem Cell Transplant
• Gene Therapy
• Other Emerging Therapies

Global Cancer Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Alkylating Agents
• Antimetabolites
• Antitumor Antibiotics
• Topoisomerase Inhibitors
• Mitotic Inhibitors
• Hormone Therapies
• Immune Checkpoint Inhibitors
• Others

Global Cancer Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical
• Others

Global Cancer Therapeutics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Skin Cancer
• Blood Cancer (Leukemia, Lymphoma, etc.)
• Gastrointestinal Cancer
• Gynecologic Cancer
• Respiratory/Lung Cancer
• Other Cancer Types

Global Cancer Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers

Global Cancer Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations